butyl (2E)-3-(4-oxo-4H-1-benzopyran-3-yl)acrylate | 1321627-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: butyl (2E)-3-(4-oxo-4H-1-benzopyran-3-yl)acrylate
• 英文别名: butyl (E)-3-(4-oxo-4H-chromen-3-yl)acrylate；(E)-butyl-3-(4-oxo-4H-chromen-3-yl)acrylate；butyl (E)-3-(4-oxochromen-3-yl)prop-2-enoate
• CAS: 1321627-88-6
• 化学式: C₁₆H₁₆O₄
• 分子量: 272.301
• InChiKey: GTXMSIGIRQZRIB-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2'-羟基苯乙酮 在 吡啶 、 硫酸 、 三氯氧磷 作用下， 反应 26.5h， 生成 butyl (2E)-3-(4-oxo-4H-1-benzopyran-3-yl)acrylate
  参考文献：
  名称：

  Synthesis, Antiproliferative, and c-Src Kinase Inhibitory Activities of 4-Oxo-4H-1-benzopyran Derivatives

  摘要：

  A new class of 4‐oxo‐4H‐1‐benzopyran derivatives were synthesized and their antiproliferative activity examined against a panel of three human cancer cell lines, that is, breast carcinoma (MDA‐MB‐468), ovarian adenocarcinoma (SK‐OV‐3), and colorectal adenocarcinoma (HT‐29). Two compounds, that is, 3‐hexyl‐7,8‐dihydroxy‐4‐oxo‐4H‐1‐benzopyran and (E)‐ethyl 3‐(7‐methoxy‐4‐oxo‐4H‐1‐benzopyran‐3‐yl)acrylate were found to be potent against all three cancer cell lines studied at 50 μM concentration. Also, the inhibitory potency of the compounds was evaluated against active Src kinase. A few of these compounds exhibited modest Src kinase inhibitory activity (IC50 = 52–57 μM). Structure‐activity relationship studies with respect to the nature and position of substituents on the lead compounds could be further exploited for the design and development of more potent antiproliferative agents and/or Src kinase inhibitors.

  DOI：

  10.1002/jhet.2106

文献信息

• The Domino Chromone Annulation and a Transient Halogenation-Mediated C–H Alkenylation toward 3-Vinyl Chromones
  作者：Leiqing Fu、Zhongrong Xu、Jie-Ping Wan、Yunyun Liu

  DOI：10.1021/acs.orglett.0c03548

  日期：2020.12.18

  Reported in this paper is a step economical method toward the general synthesis of 3-vinyl chromones via the reactions between readily available o-hydroxyphenyl enaminones and various alkenes. The domino C–H alkenylation and chromone annulation of the enaminones are involved, which enables the synthesis of 3-vinyl chromone products using both terminal and internal alkenes via a key process of transient C–H

  本文报道的是一种通过经济实用的步骤逐步实现3-乙烯基色酮的合成的方法，该方法是通过容易获得的邻-羟基苯基烯胺酮与各种烯烃之间的反应进行的。涉及烯胺酮的多米诺骨化CHH烯基化和色酮环化，这可以通过瞬态CHH卤化的关键过程使用末端烯烃和内部烯烃合成3-乙烯基色酮产物。
• Palladium(II)-Catalyzed Direct Intermolecular Alkenylation of Chromones
  作者：Donghee Kim、Sungwoo Hong

  DOI：10.1021/ol2018278

  日期：2011.8.19

  A new efficient method for the direct alkenylation of chromones via a palladium(II)-catalyzed C-H functionalization reaction was developed. The use of pivalic acid with Cu(OAc)(3)/Ag2CO3 provided superior reactivity in the cross-coupling of chromones with alkene partners. This approach represents a significant advance over the existing two-step method and afforded various 3-vinylchromone derivatives, which are privileged structures in many biologically active compounds and versatile synthetic building blocks.
• Synthesis, Antiproliferative, and c-Src Kinase Inhibitory Activities of 4-Oxo-4<i>H</i>-1-benzopyran Derivatives
  作者：Karam Chand、Rakesh K Tiwari、Sumit Kumar、Amir Nasrolahi Shirazi、Sweta Sharma、Erik V Van der Eycken、Virinder S Parmar、Keykavous Parang、Sunil K Sharma

  DOI：10.1002/jhet.2106

  日期：2015.3

  A new class of 4‐oxo‐4H‐1‐benzopyran derivatives were synthesized and their antiproliferative activity examined against a panel of three human cancer cell lines, that is, breast carcinoma (MDA‐MB‐468), ovarian adenocarcinoma (SK‐OV‐3), and colorectal adenocarcinoma (HT‐29). Two compounds, that is, 3‐hexyl‐7,8‐dihydroxy‐4‐oxo‐4H‐1‐benzopyran and (E)‐ethyl 3‐(7‐methoxy‐4‐oxo‐4H‐1‐benzopyran‐3‐yl)acrylate were found to be potent against all three cancer cell lines studied at 50 μM concentration. Also, the inhibitory potency of the compounds was evaluated against active Src kinase. A few of these compounds exhibited modest Src kinase inhibitory activity (IC50 = 52–57 μM). Structure‐activity relationship studies with respect to the nature and position of substituents on the lead compounds could be further exploited for the design and development of more potent antiproliferative agents and/or Src kinase inhibitors.